Bibliography
- Marks PA : Histone deacetylaseinhibitors: a chemical genetics approach to understanding cellular functions.Biochim. Biophys. Acta DOI: 10.1016/j.bbagrm.2010.05.008 (2010) (Epub ahead of print).
- Schrump DS : Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.Clin. Cancer Res.15(12) , 3947–3957 (2009).
- Tan J , CangS, MaY, PetrilloRL, LiuD: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.J. Hematol. Oncol.3 , 5 (2010).
- Willyard C : The saving switch.Nat. Med.16(1) , 18–21 (2010).
- Marks PA : The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Expert Opin. Investig. Drugs19(9) , 1049–1066 (2010).
- Shahbazian MD , GrunsteinM: Functions of site-specific histone acetylation and deacetylation.Annu. Rev. Biochem.76 , 75–100 (2007).
- Struhl K : Gene regulation. A paradigm for precision.Science293(5532) , 1054–1055 (2001).
- Jones PA , BaylinSB: The epigenomics of cancer.Cell128(4) , 683–692 (2007).
- Gregoretti IV , LeeYM, GoodsonHV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.J. Mol. Biol.338(1) , 17–31 (2004).
- Choudhary C , KumarC, GnadF et al.: Lysine acetylation targets protein complexes and co-regulates major cellular functions.Science325(5942) , 834–840 (2009).
- Esteller M : Epigenetics in cancer.N. Engl. J. Med.358(11) , 1148–1159 (2008).
- Parmigiani RB , XuWS, Venta-PerezG et al.: HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.Proc. Natl Acad. Sci. USA105(28) , 9633–9638 (2008).
- Haggarty SJ , KoellerKM, WongJC, GrozingerCM, SchreiberSL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.Proc. Natl Acad. Sci. USA100(8) , 4389–4394 (2003).
- Zhang X , YuanZ, ZhangY et al.: HDAC6 modulates cell motility by altering the acetylation level of cortactin.Mol. Cell27(2) , 197–213 (2007).
- Kovacs JJ , MurphyPJ, GaillardS et al.: HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor.Mol. Cell18(5) , 601–607 (2005).
- Kawaguchi Y , KovacsJJ, MclaurinA, VanceJM, ItoA, YaoTP: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.Cell115(6) , 727–738 (2003).
- Finnin MS , DonigianJR, CohenA et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.Nature401(6749) , 188–193 (1999).
- Ficner R : Novel structural insights into class I and II histone deacetylases.Curr. Top. Med. Chem.9(3) , 235–240 (2009).
- Lee JH , ChoyML, NgoL, FosterSS, MarksPA: Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.Proc. Natl Acad. Sci. USA107(33) , 14639–14644 (2010).
- Ungerstedt JS , SowaY, XuWS et al.: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Proc. Natl Acad. Sci. USA102(3) , 673–678 (2005).
- Kato T , ShimonoY, HasegawaM et al.: Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress.Cancer Res.69(8) , 3597–3604 (2009).
- Tan J , ZhuangL, JiangX, YangKK, KaruturiKM, YuQ: Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.J. Biol. Chem.281(15) , 10508–10515 (2006).
- Ma X , EzzeldinHH, DiasioRB: Histone deacetylase inhibitors: current status and overview of recent clinical trials.Drugs69(14) , 1911–1934 (2009).